TitleCARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL.
Overview / Summary
Patient eligibility criteria
Newly diagnosed MM patients ≥ 65 years old or ineligible for autologous stem cell transplant (ASCT) and able to sign the informed consent form can be enrolled.
Patients defined as fit or intermediate according to the IMWG (International Myeloma Working Group) frailty score can be included.